Clinical Trial Update: Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Neuradiab in combination with bevacizumab for recurrent glioblastoma; the status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Neuradiab

Snippet

Sponsor: Bradmer Pharmaceuticals Inc. | Conditions: Brain Tumors | Phase 2 | Status: UNKNOWN